DMIIU · Drugs Made In America Acquisition II Corp. Ordinary Shares

The Company has formalized its financing arrangement with Alpha Multi Family Office through a definitive agreement that provides $1.4 million in convertible note financing, representing a significant capital infusion for a SPAC in the pre-business combination phase. The structure includes an already-funded $150,000 bridge note, a $300,000 interim note issued March 30, 2026, and $950,000 held in escrow for future needs. The financing addresses immediate working capital requirements for audit, compliance, and transaction preparation expenses while positioning the Company to pursue its de-SPAC objective. The 35% discount conversion feature provides the Investor with substantial upside potential upon successful business combination completion, aligning interests with future shareholders. Notably, the agreement includes sponsor transition provisions acknowledging the existing sponsor's non-performance and legal constraints, suggesting governance changes may accompany the financing. The Investor's right of first refusal for additional capital and expense oversight mechanisms provide ongoing influence, though operational control remains with the Company's board. The Cayman Islands governing law indicates the Company's offshore corporate structure typical for SPACs. This financing appears critical for maintaining the Company's Nasdaq listing and advancing toward a business combination within the disclosed timelines.